Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Entera Bio Ltd.NASDAQ: ENTX
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock broadly unchanged from a year ago
Common stock stood at $1K at the end of Q1 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 1K USD
- Year-over-year change
- +0.0%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1K | +0.0% |
| FY2024 | 2024-12-31 | 1K | +0.0% |
| FY2023 | 2023-12-31 | 1K | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Common Stock vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 common stock of $1K is the 9th highest of the 10 companies compared; the peer median is $58K.
- Its year-over-year change of +0.0% is the 9th highest of 10, against a peer median of +16.7%.
- Common stock amounts to 0.0% of total assets for ENTX, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $385K | +44.7% | -51.3% | 0.2% | |
| Apr 2026 | $339K | +5.3% | +2.2% | 2.3% | |
| Mar 2026 | $69.77K | +90.3% | +48.5% | 0.1% | |
| Mar 2026 | $63.58K | +45.6% | +135.7% | 0.2% | |
| Mar 2026 | $58K | +3.6% | +2.5% | 0.1% | |
| Mar 2026 | $10K | +11.1% | -56.9% | 0.0% | |
IRDOpus Genetics, Inc. | Mar 2026 | $7K | +40.0% | +51.8% | 0.0% |
| Mar 2026 | $7K | +16.7% | +14.5% | 0.0% | |
| Mar 2026 | $1K | +0.0% | — | 0.0% | |
| Mar 2026 | $1K | +0.0% | +0.0% | 0.0% | |
| Peer median (excluding ENTX) | $58K | +16.7% | +2.5% | 0.1% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.